Posted by Michael Wonder on 26 Feb 2019
Pharma executives offer Senate ideas to lower drug costs – except actually cutting prices
26 February 2019 - High drug prices has become a rare bipartisan issue, with lawmakers on both sides of the aisle demanding change.
Executives from seven drugmakers laid out their ideas for lowering drug prices to the Senate Finance Committee on Tuesday. One idea was noticeably absent: lowering drug prices.
The companies — AbbVie, AstraZeneca, Bristol-Myers Squibb, Johnson & Johnson, Merck, Pfizer and Sanofi — threw their support behind a number of Trump administration proposals and pitched some of their own ideas in written testimony submitted ahead of the hearing. Executives championed the investments their companies make and the lives they save, while acknowledging patients cannot benefit if they can't afford medication.
